{"id":329726,"date":"2026-10-28T10:48:13","date_gmt":"2026-10-28T05:18:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=329726"},"modified":"2026-10-28T10:48:13","modified_gmt":"2026-10-28T05:18:13","slug":"midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Midcap Price to Book Above 10 Stocks to Watch for Future Multibagger Potential: Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dixon Rs 11,233. Nippon Life India AMC Rs 933.50. Navin Fluorine Rs 8,254. Dr Lal PathLabs Rs 1,901.80. Market caps from Rs 32,408 crore to Rs 75,920 crore. Data as of 27 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs are the 4 picks in this price to book above 10 stocks watchlist, with market caps between Rs 32,408 crore and Rs 75,920 crore. Dixon stands out for the fastest profit growth, 71.44% a year since FY22, while Nippon Life India AMC offers the highest return on equity at 32.83%. PE ratios run from 36.47 to 59.32, so compare each one with its industry PE before investing. All figures are as of 27 October 2026.<\/p>\n<\/p><\/div>\n<p>Price to book above 10 stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs meet that test, with market caps from Rs 32,408 crore to Rs 75,920 crore and Dixon offering the fastest profit growth, 71.44% a year since FY22. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a price to book ratio above 10, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n<p>This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and a price to book ratio above 10, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening price to book above 10 stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 27 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=price-to-book-above-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#What_Are_Price_to_Book_Above_10_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Price to Book Above 10 Stocks and Why Do They Attract Multibagger Interest?\">What Are Price to Book Above 10 Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Price_to_Book_Above_10_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Price to Book Above 10 Stocks at a Glance: Price, Market Cap, PE and ROE\">Price to Book Above 10 Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Dixon_7144_Profit_CAGR_Since_FY22\" title=\"Dixon: 71.44% Profit CAGR Since FY22\">Dixon: 71.44% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Nippon_Life_India_AMC_Return_on_Equity_of_3283\" title=\"Nippon Life India AMC: Return on Equity of 32.83%\">Nippon Life India AMC: Return on Equity of 32.83%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Navin_Fluorine_2602_Profit_CAGR_Since_FY22\" title=\"Navin Fluorine: 26.02% Profit CAGR Since FY22\">Navin Fluorine: 26.02% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Dr_Lal_PathLabs_Return_on_Equity_of_2013\" title=\"Dr Lal PathLabs: Return on Equity of 20.13%\">Dr Lal PathLabs: Return on Equity of 20.13%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Price_to_Book_Above_10_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Price to Book Above 10 Stocks: Financial Comparison on Growth and Margins\">Price to Book Above 10 Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\" title=\"Institutional Holding in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs\">Institutional Holding in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Price_to_Book_Above_10_Stocks\" title=\"Risks to Weigh in Price to Book Above 10 Stocks\">Risks to Weigh in Price to Book Above 10 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Price_to_Book_Above_10_Stocks\" title=\"How to Choose Between Price to Book Above 10 Stocks\">How to Choose Between Price to Book Above 10 Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Price_to_Book_Above_10_Stocks_to_Watch\" title=\"Frequently Asked Questions on Price to Book Above 10 Stocks to Watch\">Frequently Asked Questions on Price to Book Above 10 Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Which_are_the_best_price_to_book_above_10_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best price to book above 10 stocks to watch for multibagger potential?\">Which are the best price to book above 10 stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Is_Nippon_Life_India_AMC_a_good_stock_for_long-term_investors\" title=\"Is Nippon Life India AMC a good stock for long-term investors?\">Is Nippon Life India AMC a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Can_Dixon_become_a_multibagger_from_here\" title=\"Can Dixon become a multibagger from here?\">Can Dixon become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\" title=\"What is the market cap of Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?\">What is the market cap of Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_price_to_book_above_10_stocks\" title=\"What are the risks of investing in price to book above 10 stocks?\">What are the risks of investing in price to book above 10 stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#Why_is_Nippon_Life_India_AMC_trading_at_a_PE_of_3965\" title=\"Why is Nippon Life India AMC trading at a PE of 39.65?\">Why is Nippon Life India AMC trading at a PE of 39.65?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/midcap-price-to-book-above-10-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\" title=\"How much do institutions hold in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?\">How much do institutions hold in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Price_to_Book_Above_10_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Price to Book Above 10 Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Price to book above 10 stocks are shares that trade at more than ten times their book value, a premium that usually goes to mid sized companies with strong brands and high returns on capital. The four here cover electronics manufacturing, asset management, specialty chemicals and diagnostics.<\/p>\n<p>A high price to book ratio often marks a business whose earning power is far above what its balance sheet alone shows, such as a strong brand or a deep customer base. Within price to book above 10 stocks, the four companies show rising profit. For price to book above 10 stocks, both FY26 and the latest quarter showed growth. Whichever way you read price to book above 10 stocks, the common thread is rising profit backed by complete financial data. Investors researching price to book above 10 stocks get a fuller picture by reading growth and valuation together. The table below lines up price to book above 10 stocks on size, growth and valuation, using complete FY26 and latest quarter numbers. Past performance does not guarantee future returns, so use price to book above 10 stocks as a starting point for your own research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Price_to_Book_Above_10_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Price to Book Above 10 Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 27 October 2026. Dixon has the lowest PE of the group at 36.47, while Nippon Life India AMC posts the highest return on equity at 32.83%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/dixon\/dixon-technologies-(india)-ltd-share-price-today\">Dixon Technologies<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11,233<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">75,920<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.47<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">45.19<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">30.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.21<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,600.00 to 17,299.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/nam\/nippon-life-india-asset-management-ltd-share-price-today\">Nippon Life India Asset Management<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">933.50<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">64,905<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">39.65<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.70<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.02<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">795.80 to 1,269.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/navinfluor\/navin-fluorine-international-ltd-share-price-today\">Navin Fluorine International<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">8,254<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">42,813<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">54.22<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.42<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">16.69%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.32<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,772.20 to 8,949.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,901.80<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">32,408<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">59.32<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.13%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.08<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,272.60 to 2,038.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Dixon_7144_Profit_CAGR_Since_FY22\"><\/span><strong>Dixon: 71.44% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dixon Technologies is an electronics manufacturing services company that makes televisions, phones, appliances and lighting for brands. It reported FY26 revenue of Rs 49,585.84 crore, up 27.53% year on year, and net profit of Rs 1,644.25 crore, up 33.40%. Net profit has compounded at 71.44% a year since FY22, while revenue has grown 46.72% a year. Operating margin was 3.95% in FY26. The debt-to-equity ratio is 0.21.<\/p>\n<p>In the June 2026 quarter, revenue rose 25.23% to Rs 16,075.95 crore and net profit grew 156.35% to Rs 717.83 crore. The share price has gained 114.81% over five years. The stock trades at a PE of 36.47 against an industry PE of 45.19, below the sector average, with a return on equity of 30.76%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nippon_Life_India_AMC_Return_on_Equity_of_3283\"><\/span><strong>Nippon Life India AMC: Return on Equity of 32.83%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Nippon Life India Asset Management is one of the largest mutual fund houses in India and also runs ETFs and portfolio management services. It reported FY26 revenue of Rs 2,933.07 crore, up 16.36% year on year, and net profit of Rs 1,528.13 crore, up 18.85%. Net profit has compounded at 19.74% a year since FY22, while revenue has grown 17.56% a year. Operating margin was 68.84% in FY26. The debt-to-equity ratio is 0.02, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 39.65 against an industry PE of 17.70, with a return on equity of 32.83%. The dividend yield is 2.11%. In the June 2026 quarter, revenue rose 24.51% to Rs 937.08 crore and net profit grew 27.15% to Rs 503.09 crore. The share price has gained 131.06% over five years and 20.07% over the past year. Domestic institutions raised their holding from 13.45% in June 2025 to 15.49% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Navin_Fluorine_2602_Profit_CAGR_Since_FY22\"><\/span><strong>Navin Fluorine: 26.02% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Navin Fluorine International makes specialty fluorochemicals, refrigerant gases and contract research and manufacturing services. It reported FY26 revenue of Rs 3,379.19 crore, up 41.20% year on year, and net profit of Rs 663.56 crore, up 129.92%. Net profit has compounded at 26.02% a year since FY22, while revenue has grown 22.66% a year. Operating margin was 34.41% in FY26. The debt-to-equity ratio is 0.32.<\/p>\n<p>In the June 2026 quarter, revenue rose 46.11% to Rs 1,080.17 crore and net profit grew 107.66% to Rs 243.31 crore. The share price has gained 111.47% over five years and 61.62% over the past year. Foreign investors raised their holding from 21.98% in July 2025 to 23.73% in June 2026. The stock trades at a PE of 54.22 against an industry PE of 36.42, with a return on equity of 16.69%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Return_on_Equity_of_2013\"><\/span><strong>Dr Lal PathLabs: Return on Equity of 20.13%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Lal PathLabs is one of India&#8217;s leading diagnostic chains, running laboratories and collection centres across the country. It reported FY26 revenue of Rs 2,864.18 crore, up 12.11% year on year, and net profit of Rs 509.75 crore, up 3.56%. Net profit has compounded at 9.83% a year since FY22, while revenue has grown 7.56% a year. Operating margin was 30.90% in FY26. The debt-to-equity ratio is 0.08, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 59.32 against an industry PE of 60.75, below the sector average, with a return on equity of 20.13%. In the June 2026 quarter, revenue rose 18.87% to Rs 829.60 crore and net profit grew 27.24% to Rs 170.50 crore. The share price is up 19.11% over the past year. Domestic institutions raised their holding from 17.91% in June 2025 to 21.59% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Price_to_Book_Above_10_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Price to Book Above 10 Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these price to book above 10 stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Net Profit CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dixon<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">49,585.84<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,644.25<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.53%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">46.72%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">71.44%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.43%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Nippon Life India AMC<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,933.07<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,528.13<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">16.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.56%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.74%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">88.41%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Navin Fluorine<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,379.19<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">663.56<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">41.20%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.66%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">26.02%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">37.52%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dr Lal PathLabs<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,864.18<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">509.75<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.11%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.56%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">35.03%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these price to book above 10 stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\"><\/span><strong>Institutional Holding in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these price to book above 10 stocks alongside the promoter. The table uses the latest reported quarter for each. Navin Fluorine has the deepest institutional backing, with FII and DII together holding 52.19% as of June 2026. Domestic institutions increased their holding over the past year in Nippon Life India AMC (from 13.45% to 15.49%) and Dr Lal PathLabs (from 17.91% to 21.59%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dixon<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.50%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.96%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.71%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Nippon Life India AMC<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">71.80%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.04%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.49%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5.67%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Navin Fluorine<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.08%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.73%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.46%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.73%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dr Lal PathLabs<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">53.19%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">17.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.59%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.86%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Price_to_Book_Above_10_Stocks\"><\/span><strong>Risks to Weigh in Price to Book Above 10 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with price to book above 10 stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> Nippon Life India AMC trades at a PE of 39.65 against an industry PE of 17.70, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Price_to_Book_Above_10_Stocks\"><\/span><strong>How to Choose Between Price to Book Above 10 Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from price to book above 10 stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (17.70 to 60.75) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among price to book above 10 stocks, Dixon stands out for the fastest profit growth, 71.44% a year since FY22, Nippon Life India AMC for the highest return on equity at 32.83%, Navin Fluorine for 41.20% revenue growth in FY26 and Dr Lal PathLabs for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.08. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing price to book above 10 stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Price_to_Book_Above_10_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Price to Book Above 10 Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_price_to_book_above_10_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best price to book above 10 stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 75,920 crore, Rs 64,905 crore, Rs 42,813 crore and Rs 32,408 crore respectively. Dixon is notable for the fastest profit growth, 71.44% a year since FY22. Nippon Life India AMC stands out for the highest return on equity at 32.83%. Navin Fluorine offers 41.20% revenue growth in FY26. Dr Lal PathLabs brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.08. These are watchlist names for price to book above 10 stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Nippon_Life_India_AMC_a_good_stock_for_long-term_investors\"><\/span><strong>Is Nippon Life India AMC a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nippon Life India AMC has a return on equity of 32.83%, a PE of 39.65 against an industry PE of 17.70 and a market cap of Rs 64,905 crore. Net profit has compounded at 19.74% a year since FY22, and FY26 revenue rose 16.36% while June 2026 quarter net profit grew 27.15%. Long-term returns in price to book above 10 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Dixon_become_a_multibagger_from_here\"><\/span><strong>Can Dixon become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dixon has already gained 114.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in price to book above 10 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53%. At a PE of 36.47 against an industry PE of 45.19, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\"><\/span><strong>What is the market cap of Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 27 October 2026, Dixon has a market cap of Rs 75,920 crore, Nippon Life India AMC has a market cap of Rs 64,905 crore, Navin Fluorine has a market cap of Rs 42,813 crore and Dr Lal PathLabs has a market cap of Rs 32,408 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on price to book above 10 stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_price_to_book_above_10_stocks\"><\/span><strong>What are the risks of investing in price to book above 10 stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Nippon Life India AMC trades at a PE of 39.65 against an industry PE of 17.70, so earnings growth needs to hold up.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Nippon_Life_India_AMC_trading_at_a_PE_of_3965\"><\/span><strong>Why is Nippon Life India AMC trading at a PE of 39.65?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nippon Life India AMC&#8217;s PE of 39.65 compares with an industry PE of 17.70. The market is paying a premium for a return on equity of 32.83%, profit growth of 19.74% a year since FY22 and latest-quarter profit growth of 27.15%, which also means the stock is more sensitive if growth slows. Investors in price to book above 10 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Dixon_Nippon_Life_India_AMC_Navin_Fluorine_and_Dr_Lal_PathLabs\"><\/span><strong>How much do institutions hold in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 47.67% of Dixon (18.96% and 28.71%), 22.53% of Nippon Life India AMC (7.04% and 15.49%), 52.19% of Navin Fluorine (23.73% and 28.46%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in price to book above 10 stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best price to book above 10 stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 75,920 crore, Rs 64,905 crore, Rs 42,813 crore and Rs 32,408 crore respectively. Dixon is notable for the fastest profit growth, 71.44% a year since FY22. Nippon Life India AMC stands out for the highest return on equity at 32.83%. Navin Fluorine offers 41.20% revenue growth in FY26. Dr Lal PathLabs brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.08. These are watchlist names for price to book above 10 stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Nippon Life India AMC a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nippon Life India AMC has a return on equity of 32.83%, a PE of 39.65 against an industry PE of 17.70 and a market cap of Rs 64,905 crore. Net profit has compounded at 19.74% a year since FY22, and FY26 revenue rose 16.36% while June 2026 quarter net profit grew 27.15%. Long-term returns in price to book above 10 stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Dixon become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dixon has already gained 114.81% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in price to book above 10 stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53%. At a PE of 36.47 against an industry PE of 45.19, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 27 October 2026, Dixon has a market cap of Rs 75,920 crore, Nippon Life India AMC has a market cap of Rs 64,905 crore, Navin Fluorine has a market cap of Rs 42,813 crore and Dr Lal PathLabs has a market cap of Rs 32,408 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on price to book above 10 stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in price to book above 10 stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Nippon Life India AMC trades at a PE of 39.65 against an industry PE of 17.70, so earnings growth needs to hold up.\"}},{\"@type\":\"Question\",\"name\":\"Why is Nippon Life India AMC trading at a PE of 39.65?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nippon Life India AMC's PE of 39.65 compares with an industry PE of 17.70. The market is paying a premium for a return on equity of 32.83%, profit growth of 19.74% a year since FY22 and latest-quarter profit growth of 27.15%, which also means the stock is more sensitive if growth slows. Investors in price to book above 10 stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 47.67% of Dixon (18.96% and 28.71%), 22.53% of Nippon Life India AMC (7.04% and 15.49%), 52.19% of Navin Fluorine (23.73% and 28.46%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in price to book above 10 stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 midcap price to book above 10 stocks compared on market cap, PE, ROE, growth and institutional holding: Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs.<\/p>\n","protected":false},"author":33,"featured_media":329723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[16989,16988],"class_list":["post-329726","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-price-to-book-above-10-sector","tag-price-to-book-above-10-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["329723"],"rank_math_title":["Price to Book Above 10 Stocks 2026: Dixon, Nippon Life India AMC"],"rank_math_description":["Price to book above 10 stocks to watch for multibagger potential: Dixon, Nippon Life India AMC, Navin Fluorine and Dr Lal PathLabs. Compare PE, ROE and growth."],"rank_math_focus_keyword":["price to book above 10 stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/4-midcap-price-to-book-above-10-stocks-to-watch-for-future-multibagger-potential.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=329726"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329726\/revisions"}],"predecessor-version":[{"id":329727,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/329726\/revisions\/329727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/329723"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=329726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=329726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=329726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}